Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Renal Drug Excretion: Glomerular Filtration01:02

Renal Drug Excretion: Glomerular Filtration

490
The kidney serves as the primary organ responsible for eliminating drugs and their metabolites from the body. This process, known as renal elimination, starts with glomerular filtration and results in urine formation. Each kidney houses millions of functional units called nephrons, where urine production occurs. A nephron has two main components: a renal corpuscle and a renal tubule.
Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent arterioles....
490
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

154
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
154
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

151
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
151
这页已由机器翻译。其他页面可能仍然显示为英文。View in English
  1. 首页
  2. 研究领域
  3. 生物医学和临床科学
  4. 心血管医学和血液学
  5. 心脏病 (包括心血管疾病)
  6. 作为心力衰竭临床试验的终点,膜过率的下降:挑战和解决方案
  1. 首页
  2. 研究领域
  3. 生物医学和临床科学
  4. 心血管医学和血液学
  5. 心脏病 (包括心血管疾病)
  6. 作为心力衰竭临床试验的终点,膜过率的下降:挑战和解决方案

相关实验视频

A High-throughput Method for Measurement of Glomerular Filtration Rate in Conscious Mice
07:07

A High-throughput Method for Measurement of Glomerular Filtration Rate in Conscious Mice

Published on: May 10, 2013

43.6K

作为心力衰竭临床试验的终点,膜过率的下降:挑战和解决方案

Lesley A Inker1, Brendon L Neuen2, Wendy McCallum1

  • 1Division of Nephrology, Tufts Medical Center, 800 Washington Street, Box #391, Boston 02111, MA, USA.

European heart journal
|September 4, 2025

在PubMed 上查看摘要

概括
此摘要是机器生成的。

评估慢性病 (CKD) 在心力衰竭患者的进展需要了解膜过率 (GFR) 的变化. 早期的CKD进展终点对于试验至关重要,但解释即时GFR下降与长期益处是关键.

关键词:
慢性脏疾病GFR 的斜率淋巴细胞过率心脏衰竭

更多相关视频

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

23.8K
Physiology Lab Demonstration: Glomerular Filtration Rate in a Rat
06:58

Physiology Lab Demonstration: Glomerular Filtration Rate in a Rat

Published on: July 26, 2015

17.5K

相关实验视频

A High-throughput Method for Measurement of Glomerular Filtration Rate in Conscious Mice
07:07

A High-throughput Method for Measurement of Glomerular Filtration Rate in Conscious Mice

Published on: May 10, 2013

43.6K
5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

23.8K
Physiology Lab Demonstration: Glomerular Filtration Rate in a Rat
06:58

Physiology Lab Demonstration: Glomerular Filtration Rate in a Rat

Published on: July 26, 2015

17.5K

科学领域:

  • 科和心脏病学
  • 心血管代谢综合征
  • 临床试验的终点

背景情况:

  • 慢性病 (CKD) 和心血管疾病 (CVD) 具有共同的病理生理机制,形成心血管--代谢综合征.
  • 慢性脏病和心力衰竭 (HF) 经常同时存在,治疗策略重叠.
  • 对于个体治疗和临床试验评估来说,准确评估HF患者的慢性病进展至关重要.

研究的目的:

  • 探索评估HF患者慢性瘤进展的方法,重点关注早期代用终点.
  • 评估膜过率 (GFR) 变化作为HF结果试验的终点.
  • 在HF治疗中解释GFR波动的挑战.

主要方法:

  • 对CKD进展和HF结果的现有文献的审查.
  • 分析慢性病进展的替代终点,包括GFR斜率和值下降.
  • 通过案例研究讨论使用GFR作为HF试验的终点的挑战和可能的解决方案.

主要成果:

  • 在试验中,通过斜率或百分比降低来测量膜过率 (GFR) 的下降是认可的CKD进展的替代终点.
  • 随着指导性HF治疗,GFR可能会立即降低,从而使长期益处的评估变得复杂.
  • 仔细解释GFR变化对于评估HF试验终点和患者管理至关重要.
随机对照试验

结论:

  • 在HF结局试验中,GFR变化为CKD进展提供了有价值的早期终点.
  • 区分短暂的GFR下降和持续下降对于准确的评估至关重要.
  • 对GFR终点的标准化解释将促进HF患者的护理和临床试验设计.